7.50
price up icon2.46%   0.19
 
loading
Schlusskurs vom Vortag:
$7.31
Offen:
$7.26
24-Stunden-Volumen:
189.85K
Relative Volume:
0.09
Marktkapitalisierung:
$1.01B
Einnahmen:
$628.25M
Nettoeinkommen (Verlust:
$-78.55M
KGV:
-12.10
EPS:
-0.62
Netto-Cashflow:
$-29.73M
1W Leistung:
+3.60%
1M Leistung:
+2.88%
6M Leistung:
-54.55%
1J Leistung:
-46.23%
1-Tages-Spanne:
Value
$7.155
$7.61
1-Wochen-Bereich:
Value
$6.97
$7.61
52-Wochen-Spanne:
Value
$6.08
$19.11

Neogenomics Inc Stock (NEO) Company Profile

Name
Firmenname
Neogenomics Inc
Name
Telefon
(239) 768-0600
Name
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Name
Mitarbeiter
2,200
Name
Twitter
@NeoGenomics
Name
Nächster Verdiensttermin
2025-02-18
Name
Neueste SEC-Einreichungen
Name
NEO's Discussions on Twitter

Vergleichen Sie NEO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
NEO
Neogenomics Inc
7.50 1.01B 628.25M -78.55M -29.73M -0.62
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
412.70 156.49B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
198.96 145.01B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
536.45 42.30B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
118.75 34.24B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
159.37 27.64B 15.50B 1.33B 2.16B 7.34

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-15 Eingeleitet Guggenheim Neutral
2025-04-30 Herabstufung Leerink Partners Outperform → Market Perform
2025-01-13 Herabstufung The Benchmark Company Buy → Hold
2024-12-10 Eingeleitet Jefferies Buy
2024-05-01 Fortgesetzt Craig Hallum Buy
2023-12-29 Bestätigt BTIG Research Buy
2023-08-21 Hochstufung Stephens Equal-Weight → Overweight
2023-05-16 Herabstufung Raymond James Outperform → Mkt Perform
2023-05-09 Hochstufung BTIG Research Neutral → Buy
2023-02-24 Hochstufung The Benchmark Company Hold → Buy
2023-02-01 Hochstufung Needham Hold → Buy
2022-08-26 Herabstufung The Benchmark Company Buy → Hold
2022-08-22 Herabstufung Needham Buy → Hold
2022-06-03 Eingeleitet Piper Sandler Overweight
2022-03-29 Herabstufung BofA Securities Buy → Neutral
2022-03-29 Herabstufung Stephens Overweight → Equal-Weight
2022-01-18 Fortgesetzt Stephens Overweight
2021-12-16 Eingeleitet Cowen Outperform
2021-11-05 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-10-14 Hochstufung Raymond James Mkt Perform → Outperform
2021-06-03 Eingeleitet Goldman Buy
2021-02-25 Fortgesetzt Needham Buy
2021-02-25 Herabstufung Raymond James Outperform → Mkt Perform
2021-01-28 Eingeleitet Truist Buy
2020-12-11 Fortgesetzt BTIG Research Buy
2020-10-28 Bestätigt Needham Buy
2020-09-09 Eingeleitet Morgan Stanley Overweight
2020-08-28 Eingeleitet Guggenheim Buy
2020-07-29 Bestätigt Needham Buy
2020-06-25 Eingeleitet BofA/Merrill Buy
2020-04-21 Fortgesetzt Stephens Overweight
2020-03-02 Fortgesetzt Craig Hallum Buy
2020-02-28 Hochstufung First Analysis Sec Outperform → Strong Buy
2020-01-23 Herabstufung First Analysis Sec Strong Buy → Outperform
2019-10-30 Bestätigt Needham Buy
2019-05-01 Bestätigt Needham Buy
2019-03-29 Bestätigt Needham Buy
2019-01-03 Eingeleitet Needham Buy
2018-10-24 Hochstufung First Analysis Sec Outperform → Strong Buy
2018-08-21 Eingeleitet Leerink Partners Outperform
2018-05-02 Herabstufung First Analysis Sec Overweight → Equal-Weight
2017-09-11 Herabstufung BTIG Research Buy → Neutral
2017-08-24 Eingeleitet Gabelli & Co Buy
2016-12-15 Eingeleitet Cantor Fitzgerald Overweight
Alle ansehen

Neogenomics Inc Aktie (NEO) Neueste Nachrichten

pulisher
Jun 18, 2025

NeoGenomics' Market Cap Drops To US$954m Leaving Insiders With Losses - simplywall.st

Jun 18, 2025
pulisher
Jun 18, 2025

NeoGenomics Requests to Dismiss Class Action Filed by Investors - TradingView

Jun 18, 2025
pulisher
Jun 18, 2025

NeoGenomics drops as sequential revenue decline leads to Q1 miss - MSN

Jun 18, 2025
pulisher
Jun 06, 2025

NeoGenomics Schedules its First Quarter 2021 Earnings Release for May 5, 2021 - ACCESS Newswire

Jun 06, 2025
pulisher
Jun 03, 2025

Investor Calendar Invites You to the NeoGenomics Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Tuesday March 1, 2016 - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

NeoGenomics at William Blair Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

NeoGenomics at William Blair Conference: Strategic Growth and Innovation - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Where are the Opportunities in (NEO) - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 02, 2025

Cancer Tumor Profiling Market Rises with Demand - openPR.com

Jun 02, 2025
pulisher
Jun 02, 2025

Liquid Biopsy Market for Cancer Detection, cfDNA & CTC Analysis | - openPR.com

Jun 02, 2025
pulisher
May 29, 2025

Fort Myers-based NeoGenomics to unveil new cancer diagnostics at ASCO 2025 - Gulfshore Business

May 29, 2025
pulisher
May 29, 2025

NeoGenomics unveils new oncology diagnostics at ASCO 2025 By Investing.com - Investing.com South Africa

May 29, 2025
pulisher
May 28, 2025

Neogenomics director Kelly buys $38,000 in common stock - Investing.com Australia

May 28, 2025
pulisher
May 28, 2025

Neogenomics director Kelly buys $38,000 in common stock By Investing.com - Investing.com Nigeria

May 28, 2025
pulisher
May 28, 2025

NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025 - BioSpace

May 28, 2025
pulisher
May 28, 2025

NeoGenomics unveils new oncology diagnostics at ASCO 2025 - Investing.com

May 28, 2025
pulisher
May 27, 2025

NeoGenomics Approves Key Proposals at Annual Meeting - TipRanks

May 27, 2025
pulisher
May 25, 2025

D. E. Shaw & Co. Inc. Trims Stock Position in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

May 25, 2025
pulisher
May 24, 2025

BNP Paribas Financial Markets Sells 35,979 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

May 24, 2025
pulisher
May 24, 2025

NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of “Hold” from Analysts - Defense World

May 24, 2025
pulisher
May 23, 2025

NeoGenomics introduces c-MET companion diagnostic for NSCLC - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper - simplywall.st

May 23, 2025
pulisher
May 22, 2025

NeoGenomics launches rapid c-MET diagnostic test for NSCLC - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

NeoGenomics launches rapid c-MET diagnostic test for NSCLC By Investing.com - Investing.com South Africa

May 22, 2025
pulisher
May 22, 2025

Neogenomics Launches C-Met Cdx Assay To Guide Treatment Decisions For Advanced Non-Small Cell Lung Cancer - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer - Business Wire

May 22, 2025
pulisher
May 22, 2025

Ameriprise Financial Inc. Reduces Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

May 22, 2025
pulisher
May 21, 2025

Envista, NeoGenomics, Acadia Healthcare, Astrana Health, and Hims & Hers Health Stocks Trade Down, What You Need To Know - Yahoo Finance

May 21, 2025
pulisher
May 20, 2025

ESR1 Mutated Metastatic Breast Cancer Diagnostics Market - openPR.com

May 20, 2025
pulisher
May 20, 2025

NeoGenomics to Participate in Upcoming June Investor Conferences - Bluefield Daily Telegraph

May 20, 2025
pulisher
May 20, 2025

Leading Oncology Testing Firm NeoGenomics Announces Key June Investor Conference Schedule - Stock Titan

May 20, 2025
pulisher
May 20, 2025

3 Healthcare Stocks with Mounting Challenges - FinancialContent

May 20, 2025
pulisher
May 17, 2025

Guggenheim Begins Coverage on NeoGenomics (NASDAQ:NEO) - Defense World

May 17, 2025
pulisher
May 16, 2025

NeoGenomics To Present At 39th Annual William Blair Growth Stock Conference - ACCESS Newswire

May 16, 2025
pulisher
May 15, 2025

NeoGenomics opposes US PTAB discretionary denial, citing public health concerns - MLex

May 15, 2025
pulisher
May 15, 2025

Guggenheim Begins Coverage of NeoGenomics (NEO) with Neutral Stance | NEO Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Guggenheim Initiates Coverage on NeoGenomics With Neutral Rating - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

NeoGenomics (NEO) Initiated with Neutral Rating by Guggenheim Analyst | NEO Stock News - GuruFocus

May 15, 2025
pulisher
May 14, 2025

NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Tower Research Capital LLC TRC - Defense World

May 14, 2025
pulisher
May 13, 2025

NEO Q1 Earnings Call: Sales Growth, Pharma Headwinds, and Pathline Integration Shape Outlook - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

NeoGenomics (NASDAQ:NEO) Upgraded to Hold at StockNews.com - Defense World

May 13, 2025
pulisher
May 10, 2025

Insider Buying: Stephen Kanovsky Acquires Shares of NeoGenomics Inc (NEO) - GuruFocus

May 10, 2025
pulisher
May 09, 2025

Chief Financial Officer of NeoGenomics Jeffrey Sherman Buys 14% More Shares - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in oncology using the UG 100 sequencing platform - SelectScience

May 09, 2025
pulisher
May 08, 2025

NeoGenomics, Inc. to Host Earnings Call - ACCESS Newswire

May 08, 2025
pulisher
May 07, 2025

Insider Buying: Neil Gunn Acquires Shares of NeoGenomics Inc (NE - GuruFocus

May 07, 2025

Finanzdaten der Neogenomics Inc-Aktie (NEO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Neogenomics Inc-Aktie (NEO) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
KANOVSKY STEPHEN M
Director
Jun 01 '25
Option Exercise
0.00
12,254
0
52,344
Kelly Michael Aaron
Director
Jun 01 '25
Option Exercise
0.00
12,254
0
44,009
TETRAULT LYNN A.
Director
Jun 01 '25
Option Exercise
0.00
12,254
0
73,652
Floegel Elizabeth
Director
Jun 01 '25
Option Exercise
0.00
12,254
0
23,590
Gunn Neil
Director
Jun 01 '25
Option Exercise
0.00
12,254
0
28,100
Zook Anthony P.
Chief Executive Officer
Jun 01 '25
Option Exercise
0.00
12,254
0
23,590
Perez David Brian
Director
Jun 01 '25
Option Exercise
0.00
12,254
0
33,890
Kelly Michael Aaron
Director
May 27 '25
Buy
7.60
5,000
38,000
5,000
Olivo Alicia C
EVP, GC & Business Development
May 11 '25
Option Exercise
0.00
6,503
0
51,204
Sherman Jeffrey Scott
Chief Financial Officer
May 11 '25
Option Exercise
0.00
13,005
0
171,499
diagnostics_research DGX
$179.36
price down icon 0.22%
diagnostics_research WAT
$349.48
price up icon 0.25%
diagnostics_research LH
$262.68
price up icon 0.08%
$165.77
price down icon 2.31%
diagnostics_research MTD
$1,172.90
price up icon 1.15%
diagnostics_research IQV
$158.51
price up icon 0.58%
Kapitalisierung:     |  Volumen (24h):